Drugs / JDB0131
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07170800 | Sep 2025 → Feb 2026 overdue | multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | WestVac Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06224036 | Oct 2023 → Mar 2024 | drug-resistant tuberculosis | Beijing Chest Hospital | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JDB0131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06224036 ↗ |
| Modality | Small molecule | “JDB0131 is a novel, structurally optimized third-generation nitroimidazole antituberculosis agent” PMID 41461639 ↗ Dec 2025 |
| Route | Oral | “JDB0131 benzenesulfonate tablet taken orally by drug sensitive pulmonary tuberculosis patients” NCT06224036 ↗ |